Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases

JIANBIN WANG, PING LIANG, JIE YU, MING-AN YU, FANGYI LIU, ZHIGANG CHENG and XIAOLING YU

Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing 100853, P.R. China

Received October 8, 2013; Accepted March 27, 2014

DOI: 10.3892/ol.2014.2106

Abstract. The present study aimed to assess the feasibility, safety and efficiency of ultrasound-guided percutaneous microwave ablation (MWA) on liver metastases from colon or rectal cancer. Patients who received MWA therapy for liver metastases from colon or rectal cancer between June 2009 and May 2012 were enrolled in the study. Follow-up data was collected from the patients in order to statistically analyze the adverse effects, concurrent disease and survival status. Of the total 115 patients, 62 presented with colon cancer and 53 with rectal cancer. A total of 78 patients were male and 37 were female. The patient age ranged between 30 and 86 years [mean ± standard deviation (SD), 59.46±11.79 years]. The number of overall ablation lesions was 165, and the diameter of the lesions ranged between 1.3 and 5.0 cm (mean ± SD, 3.10±1.05 cm). Subsequent to treatment, the mean (± SD) hospitalization time was 4.69±2.08 days (range, 2-10 days). The median follow-up time was 28 months (range, 12 -48 months) and 5 patients were lost to follow-up. The pain grade was recorded between the 4th and 6th degree following treatment in 23 patients. The body temperatures of 35 patients reached >38°C, with the longest time at this temperature recorded as 5 days. Following treatment, 5 patients presented with pleural effusion and required thoracocentesis and drainage. Following ablation, the rate of local progression was 11.82%. The recurrence rates were 27.8, 48.4 and 59.3% and the cumulative survival rates were 98.1, 87.1 and 78.7% in years 1, 2 and 3 post-treatment, respectively. A total of 14 patients succumbed. No significant differences were observed in the liver metastases of colorectal cancer with regard to gender, age, number of lesions, lesion size and pathological differentiation (P>0.05). Also, no significant difference was observed in the recurrence or cumulative survival rates for years 1, 2 and 3 years post-treatment (P>0.05). In conclusion, ultrasound-guided percutaneous MWA is a safe and competent way to treat inoperable colorectal liver metastases.

Introduction

Colorectal cancer is a malignancy with high incidence. The main cause of mortality is metastases, and the liver is the most common target organ in colorectal cancer (1). In total, 20-25% of colorectal cancer patients are diagnosed with liver metastases, and another 20-25% with metachronous hepatic metastases. The main method used to treat colorectal liver metastases (CRLM) is hepatectomy, however, only 10-20% patients are suitable for this procedure (2). Image-guided thermal ablation has been developed and is now widely used to treat liver tumors. Additionally, radiofrequency ablation (RFA) is a safe, well-tolerated, repeatable and less invasive approach to treat CRLM (3,4). Whilst, microwave ablation (MWA) is highly valued, as it has a wide ablation diameter, high ablation rates, low heat sink effect and short duration (5,6), the available studies of MWA on CRLM are fewer in number than those of RFA. The present study aimed to assess the feasibility, safety and efficiency of ultrasound-guided percutaneous microwave ablation (MWA) on liver metastases from colon or rectal cancer.

Materials and methods

Patients. All patients enrolled in the present study were treated for CRLM using ultrasound-guided percutaneous MWA between June 2009 and May 2012 in the Department of Interventional Ultrasound, in the Chinese People's Liberation Army General Hospital (Beijing, China). The study was approved by the ethics committee of Chinese PLA General Hospital (Beijing, China). The study was approved by the ethics committee of Chinese PLA General Hospital (Beijing, China).

Inclusion criteria. To be eligible for MWA, the following inclusion criteria were used: Tumor diameters of <5 cm for single liver tumors; tumor diameters of <3 cm for 2-3 tumors; no invasion of the blood vessels, bile duct and adjacent organs; no distant metastasis; and normal coagulation.

Treatment. All necessary examinations were performed prior to the treatment, and signed informed consent was obtained from each patient. Liver lesions were clearly displayed upon two-dimensional ultrasound, and if the image was not clear, it

Correspondence to: Dr Ping Liang, Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, P.R. China
E-mail: liangping301@hotmail.com

Key words: microwave ablation, ultrasound-guided, liver metastases, colorectal cancer
was located by contrast-enhanced ultrasound. All the patients were treated with intravenous anesthesia, a cooled-shaft micro-wave system (KY-2000; Kangyou Medical, Nanjing, Jiangsu, China), two coaxial cables and two water-pumping machines, which could simultaneously drive two 15-gauge polytetrafluorethylene-coated cooled-shaft antennae. The generators were able to produce 1-100 W of power at 2,450 MHz. Three types of antennae, with 0.5, 0.7 and 1.1 cm tips, were chosen according to the size of the tumor, diameter <2, 2-3 and >3 cm, respectively. A thermal monitoring system with 21-gauge thermocouple needles was equipped in the MWA machine. These needles function by monitoring the real-time temperature percutaneously at a specified location (7,8).

Follow-up visits. Subsequent to 3 days of treatment, all patients were examined by contrast-enhanced ultrasound to determine the inactivated condition of the tumor and to establish whether any supplementary treatment was required. Subsequent to this, changes in the pain grade and temperature, and results of routine blood and liver function tests were observed. The patients were examined by enhanced computed tomography (CT)/magnetic resonance imaging (MRI) or ultrasound imaging in months 1, 3, 6, 9 and 12 post-treatment. A follow-up study was performed every 3-6 months.

Results

Baseline data. From a total of 180 patients, 115 were enrolled in the present study according to the inclusion criteria. A total of 62 patients presented with colon cancer and 53 with rectal cancer. Highly-differentiated cancer was detected in 10 patients, moderately-differentiated in 76 and poorly-differentiated in 29. The patients consisted of 78 males and 37 females. The age range was between 30 and 86 years old [mean ± standard deviation (SD), 59.46±11.79]. There were 165 ablation lesions, with diameters ranging between 1.3 and 5.0 cm (mean ± SD, 3.10±1.05 cm); 85 lesions were ablated once and 80 lesions were ablated twice. The mean (± SD) power level used was 50.3±7.2 W (range, 45-60 W) and the mean (± SD) duration of treatment was 5.6±2.7 min (range, 2-8 min). Following treatment, the mean (± SD) hospitalization time was 4.69±2.08 days (range, 2-10 days). According to the location of the liver metastasis, two groups were defined: The colon cancer group and the rectal cancer group.

Comparison of baseline data between colon and rectal cancer groups. No significant differences were observed between the colon and rectal cancer groups with regard to gender, age, number of lesions, lesion size, pathological differentiation or hospitalization time following ablation (P>0.05; Table I).

Comparison of recurrence and cumulative survival rates between colon and rectal cancer groups. Up to May 2013, the patients had been followed up for 28 months (median follow-up time; range, 12-48). A total of 5 cases were lost to follow up, with a rate of 4.35%. Subsequent to ablation, 13 cases exhibited intrahepatic lesions, 14 cases exhibited new liver lesions and 23 cases manifested other organ metastases. In total, 14 patients succumbed; 9 due to respiratory failure, 4 due to failure of liver function and 1 due to cerebral hemorrhage. The cumulative recurrence rates were 27.8, 48.4 and 59.3% and the cumulative survival rates were 98.1, 87.1 and 78.7% in years 1, 2 and 3 years post-treatment, respectively. No significant differences were observed between the cumulative recurrence and cumulative survival rates between the two groups (P>0.05) (Table I).

Major adverse reactions following ablation. Following ablation, adverse reactions were mainly recorded as regional pain, fever and hepatic insufficiency. The pain grade was recorded between the 4th and 6th degree following treatment in 23 patients. The body temperature of 35 patients was >38°C, with the longest period at this temperature recorded as lasting for 5 days. A total of 5 cases required thoracocentesis and
drainage for pleural effusions (3 patients with colon cancer and 2 with rectal cancer). No significant difference was observed in the white blood cell count, alanine aminotransferase level, presence of fever, time >38°C or pain grade between the two groups (P>0.05). Additionally, no patients suffered hepatic abscesses, peritonitis, other infections or succumbed to the treatment. The principal adverse reactions of the colon and rectal cancer groups following ablation are shown in Table III.

**Discussion**

The disease incidence of colorectal cancer is high, and 40-50% of colorectal cancer patients will develop liver metastases (9). Currently, the main way to treat CRLM is via excision. The 5-year survival rate can reach 30-40%, however, only 20% of patients with liver metastases can be completely cured (10). Patients with unresectable CRLM have previously been shown to live on average for only 8-10 months without treatment, with a 5-year survival rate of <5%. With the application of chemotherapeutics and new target drugs, this survival rate has been shown to be enhanced to 20-24 months, and a few of the CRLM patients in whom it was first believed that excision could not be performed have been found to be able to withstand a resection with curative intent (11,12). However, following chemotherapy, the condition of the patients generally changes. Minimally invasive treatment has become a reasonable choice for the majority of patients who reject liver tumor resection.

In the past two decades, ultrasound-guided minimally invasive treatment has developed so fast that transarterial chemoembolisation (TACE) and thermal ablation therapy have become widely used. TACE is used merely as a palliative therapy when CRLM cannot be excised or the patient rejects surgery (13). However, thermal ablation therapy has become one of the main therapies to cure CRLM, and RFA has been a more recent alternative treatment method. RFA is able to excise a single CRLM (diameter, <3 cm) and has an effect equal to that of direct excision. Moreover, with regard to the small tumors that are difficult to reach and hide in the depths of the liver, RFA, to a certain extent, can treat CRLM better than direct excision (14,15). As is shown by a number of studies of RFA on unresectable CRLM, the 3-year survival rates range between 37 and 77%, while the 5-year rates are between 27 and 36% (16-18). Due to intrahepatic micrometastases and incomplete tumor destruction, the use of RFA is associated with the risk of intrahepatic and local disease recurrence (19). Certain studies of liver recurrence patterns for CRLM following RFA have indicated intrahepatic recurrence rates of between 32 and 62.5% (14,20-22).

Compared with RFA, MWA has the merit of faster local heating and a wider range of ablation zone (23,24). MWA can be used with multiple probes rendering larger tissues down in size in a shorter time. Due to active heating, MWA, unlike RFA, is not affected by charred and desiccated tissue at the tip of the probe, leading to more uniform and reliable tissue

---

**Table II. Comparison of recurrence rate and mortality rate between colon and rectal cancer groups.**

| Group | 1-year | 2-year | 3-year | 1-year | 2-year | 3-year |
|-------|--------|--------|--------|--------|--------|--------|
| Colon, % | 30.0 | 48.1 | 61.1 | 98.4 | 88.6 | 78.7 |
| Rectal, % | 36.0 | 49.7 | 57.5 | 97.9 | 85.8 | 78.6 |
| P-value | 0.441 | 0.908 | 0.749 | 0.546 | 0.744 | 0.812 |

**Table III. Comparison of adverse reaction between two groups.**

| Parameter | Colon (n=62) | Rectal (n=53) | P-value |
|-----------|-------------|---------------|---------|
| WBC on 1st day, x10^9/l | 9.36±3.65 | 8.44±3.62 | 0.182 |
| ALT on 1st day, U/l | 171.45±103.65 | 195.59±122.18 | 0.254 |
| Fever | | | 0.884 |
| None | 19 | 15 | \ |
| <38°C | 24 | 22 | \ |
| ≥38°C | 19 | 16 | \ |
| Time >38°C, days | 0.87±1.38 | 0.78±1.24 | 0.748 |
| Pain grade | | | 0.839 |
| 0 | 35 | 32 | \ |
| 1-3 | 14 | 11 | \ |
| 4-6 | 13 | 10 | \ |

WBC, white blood cells; ALT, alanine aminotransferase.
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J and Bouvier AM: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244: 254-259, 2006.
3. Wu YZ, Li B, Wang T, Wang SJ and Zhou YM: Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol 17: 4143-4148, 2011.
4. Gillams AR and Lees WR: Radiofrequency ablation of colorectal liver metastases. Abdom Imaging 30: 419-426, 2005.
5. Wright AS, Sampson LA, Warner TF, Mahvi DM and Lee FT Jr: Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 236: 132-139, 2005.
6. McWilliams JP, Lee EW, Yamamoto S, Loh CT and Kee ST: Image-guided tumor ablation: emerging technologies and future directions. Semin Intervent Radiol 27: 302-313, 2010.
7. Dong BW, Liang P, Yu XL, et al: Sonographically guided microwave coagulation treatment of liver cancer: an experimental and clinical study. AJR Am J Roentgenol 171: 449-454, 1998.
8. Liang P, Wang Y, Yu X and Dong B: Malignant liver tumors: treatment with percutaneous microwave ablation - complications among cohort of 1136 patients. Radiology 251: 933-940, 2009.
9. Cummings LC, Payes JD and Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 109: 718-726, 2007.
10. Janss RJ, Wicherts DA, Andreani P, et al: Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg 253: 1069-1079, 2011.
11. Leonard GD, Brenner B and Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23: 2038-2048, 2005.
12. Kemeny N: Presurgical chemotherapy in patients being considered for liver resection. Oncologist 12: 825-839, 2007.
13. Martin RC, Robbins K, Tomalty D, et al: Transarterial chemo-embolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7: 80, 2009.
14. Hur H, Ko YT, Min BS, et al: Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197: 728-736, 2009.
15. Pathak S, Jones R, Tang JM, et al: Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis 13: e252-e265, 2011.
16. Van Tilborg AG, Meijerink MR, Sietsees C, et al: Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol 84: 556-565, 2011.
17. Siperstein AE, Berber E, Ballem N and Parikh RT: Survival after radio-frequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246: 559-567, 2007.
18. Sörensen SM, Mortensen FV and Nielsen DT: Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 48: 253-258, 2007.
19. Gwak JH, Oh BY, Lee RA, Chung SS and Kim KH: Clinical applications of radio-frequency ablation in liver metastasis of colorectal cancer. J Korean Soc Coloproctol 27: 202-210, 2011.
20. Wong SL, Mangu PB, Choti MA, et al: American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28: 493-508, 2010.
21. Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pélissier S and Evrard S: Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol 34: 185-190, 2008.
22. Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD and Pawlik TM: Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 143: 1204-1212, 2008.
23. Vogl TJ, Zegelman A, Bechstein WO, Zeuzem S and Zangos S: Treatment of liver metastases of colorectal carcinoma: overview of hyperthermal ablation methods. Dtsch Med Wochenschr 138: 792-798, 2013 (In German).
24. Yu J, Liang P, Yu X, Liu F, Chen L and Wang Y: A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol 79: 124-130, 2011.
25. Gravante G, Ong SL, Metcalfe MS, Strickland A, Dennison AR and Lloyd DM: Hepatic microwave ablation: a review of the histological changes following thermal damage. Liver Int 28: 911-921, 2008.
26. Li M, Yu XL, Liang P, Liu F, Dong B and Zhou P: Percutaneous microwave ablation for liver cancer adjacent to the diaphragm. Int J Hyperthermia 28: 218-226, 2012.
27. Yu J, Liang P, Yu XL, Cheng ZG, Han ZY and Dong BW: Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. Eur J Radiol 81: 2495-2499, 2012.